<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484003</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981CZA01</org_study_id>
    <nct_id>NCT00484003</nct_id>
  </id_info>
  <brief_title>A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis</brief_title>
  <official_title>A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and effect of pimecrolimus cream 1% on quality of life of
      caregivers of South African children with mild to moderate atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life assessment on scheduled visits at Day 1 (Baseline), Day 14 and Day 90 or day of early discontinuation visit.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data will be collected by monitoring and recording all adverse events (AEs)and Serious Adverse Events(SAEs) throughout the duration of the trial.</measure>
  </secondary_outcome>
  <condition>Atopic Eczema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus cream 1%</intervention_name>
    <other_name>Elidel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age ≥2 years ≤12 years of age

          -  Atopic dermatitis on sensitive skin areas only ( i.e. face , neck and flexures )

          -  Subjects in whom other treatment modalities are inadvisable according to the
             investigator's clinical opinion or have failed on other treatment modalities due to
             intolerance or inadequate response.

          -  Patients with a history of mild to moderate AD

          -  Subjects should present at visit 1 with a clear clinical diagnosis of mild to moderate
             AD.

          -  Subject's parents or legal guardian must have been informed of the study procedures
             and must have signed the Informed Consent form approved for the study prior to any
             study related procedures

        Exclusion Criteria:

          -  Subjects who have active viral infections at the site(s) of treatment. In the presence
             of other dermatological infections, the use of appropriate antimicrobial agents should
             be instituted.

          -  Subjects who present with systemic malignancy or active lymphoproliferative
             diseases/disorders (e.g., lymphoma, neoplastic disease, chronic lymphoproliferation).

          -  Subjects who present with clinical conditions other than AD that can, in the opinion
             of the investigator, interfere with the evaluation

          -  Subjects who are receiving photo-therapy (e.g., PUVA, UVB) or immunosuppressive
             therapy (e.g., cyclosporine, FK-506 [tacrolimus]).

          -  Subjects who have used investigational drugs within 8 weeks prior to first application
             of study medication or intended use of other investigational drugs during the course
             of this study.

          -  Subjects who have used, or are using 0.03% or 0.1% tacrolimus ointment.

          -  Pimecrolimus cream 1% is contraindicated in subjects who have known or suspected
             hypersensitivity to pimecrolimus or any components of the cream

          -  Subjects not medically stable or subjects with any condition which, in the opinion of
             the investigator, should render the subject ineligible for the study.

          -  Pregnancy and lactation (if applicable)

          -  Pimecrolimus cream 1% should not be used during pregnancy or lactation

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Sites</name>
      <address>
        <city>Various Cities</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Atopic eczema</keyword>
  <keyword>Pimecrolimus</keyword>
  <keyword>Children</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Safety</keyword>
  <keyword>Atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

